EC Number | Protein Variants | Comment | Organism |
---|---|---|---|
1.5.1.3 | A16V | point mutation of the active site residue leads to a widespread resistance of the parasite to the drugs cycloguanil and pyrimethamine | Plasmodium falciparum |
1.5.1.3 | C59R | point mutation of the active site residue leads to a widespread resistance of the parasite to the drugs cycloguanil and pyrimethamine | Plasmodium falciparum |
1.5.1.3 | I164X | point mutation of the active site residue leads to a widespread resistance of the parasite to the drugs cycloguanil and pyrimethamine | Plasmodium falciparum |
1.5.1.3 | N51I | point mutation of the active site residue leads to a widespread resistance of the parasite to the drugs cycloguanil and pyrimethamine | Plasmodium falciparum |
1.5.1.3 | S108N | point mutation of the active site residue leads to a widespread resistance of the parasite to the drugs cycloguanil and pyrimethamine | Plasmodium falciparum |
1.5.1.3 | S108T | point mutation of the active site residue leads to a widespread resistance of the parasite to the drugs cycloguanil and pyrimethamine | Plasmodium falciparum |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
1.5.1.3 | Chloroquine | - |
Plasmodium falciparum | |
1.5.1.3 | cycloguanil | an antifolate enzyme inhibitor used in treatment of malaria | Plasmodium falciparum | |
1.5.1.3 | additional information | design and development of enzyme inhibitors based on on the bioactive conformation of WR99210 extracted from the X-ray crystal structure of quadruple mutant parasite DHFR enzyme, virtual screening and molecular docking, overview | Plasmodium falciparum | |
1.5.1.3 | NCI0086195 | docking analysis, overview | Plasmodium falciparum | |
1.5.1.3 | NCI0109835 | docking analysis, overview | Plasmodium falciparum | |
1.5.1.3 | NCI0156252 | docking analysis, overview | Plasmodium falciparum | |
1.5.1.3 | NCI0164641 | docking analysis, overview | Plasmodium falciparum | |
1.5.1.3 | NCI0211175 | docking analysis, overview | Plasmodium falciparum | |
1.5.1.3 | NCI0289533 | docking analysis, overview | Plasmodium falciparum | |
1.5.1.3 | NCI0289541 | docking analysis, overview | Plasmodium falciparum | |
1.5.1.3 | NCI0309401 | docking analysis, overview | Plasmodium falciparum | |
1.5.1.3 | NCI0369769 | docking analysis, overview | Plasmodium falciparum | |
1.5.1.3 | NCI0696662 | docking analysis, overview | Plasmodium falciparum | |
1.5.1.3 | pyrimethamine | an antifolate enzyme inhibitor used in treatment of malaria | Plasmodium falciparum | |
1.5.1.3 | WR99210 | docking analysis, overview | Plasmodium falciparum |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
1.5.1.3 | 7,8-dihydrofolate + NADPH + H+ | Plasmodium falciparum | - |
5,6,7,8-tetrahydrofolate + NADP+ | - |
r |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
1.5.1.3 | Plasmodium falciparum | - |
- |
- |
EC Number | Reaction | Comment | Organism | Reaction ID |
---|---|---|---|---|
1.5.1.3 | 5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+ | Ala16, Ile51, Cys59, Ser108 and Ile164 are active site residues | Plasmodium falciparum |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
1.5.1.3 | 7,8-dihydrofolate + NADPH + H+ | - |
Plasmodium falciparum | 5,6,7,8-tetrahydrofolate + NADP+ | - |
r |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
1.5.1.3 | DHFR | - |
Plasmodium falciparum |
EC Number | Cofactor | Comment | Organism | Structure |
---|---|---|---|---|
1.5.1.3 | NADP+ | - |
Plasmodium falciparum | |
1.5.1.3 | NADPH | - |
Plasmodium falciparum |